Virus-Specific Regulatory T Cells Ameliorate Encephalitis by Repressing Effector T Cell Functions from Priming to Effector Stages

34Citations
Citations of this article
43Readers
Mendeley users who have this article in their library.

Abstract

Several studies have demonstrated the presence of pathogen-specific Foxp3+ CD4 regulatory T cells (Treg) in infected animals, but little is known about where and how these cells affect the effector T cell responses and whether they are more suppressive than bulk Treg populations. We recently showed the presence of both epitope M133-specific Tregs (M133 Treg) and conventional CD4 T cells (M133 Tconv) in the brains of mice with coronavirus-induced encephalitis. Here, we provide new insights into the interactions between pathogenic Tconv and Tregs responding to the same epitope. M133 Tregs inhibited the proliferation but not initial activation of M133 Tconv in draining lymph nodes (DLN). Further, M133 Tregs inhibited migration of M133 Tconv from the DLN. In addition, M133 Tregs diminished microglia activation and decreased the number and function of Tconv in the infected brain. Thus, virus-specific Tregs inhibited pathogenic CD4 T cell responses during priming and effector stages, particularly those recognizing cognate antigen, and decreased mortality and morbidity without affecting virus clearance. These cells are more suppressive than bulk Tregs and provide a targeted approach to ameliorating immunopathological disease in infectious settings.

Figures

  • Figure 1. M133 Tregs, but not bulk Tregs proliferate and are recruited to the brains of rJ2.2-infected mice. (A) Blood was obtained from B6-Foxp3gfp and M133 Tg-Foxp3gfp mice and analyzed for presence of M133-specific Tregs and Tconv using I-Ab/M133 tetramers. Representative plots after gating on CD4 T cells are shown. (B) Experimental design. Bulk and M133 Tregs were purified by flow cytometry from the spleen and LNs of Foxp3gfp and M133 Tg-Foxp3gfp mice, respectively, mixed at a 1:1 ratio and labeled with Violet. A total of 36105 cells were transferred to CD45/Thy1 congenic mice one day prior to infection with rJ2.2. (C) Gating strategy for identification of M133 and bulk Tregs in recipient mice is shown. (D) Representative plots showing proliferation of cells in the indicated tissues at day 7 p.i. The box in each panel indicates cells that have proliferated. N.D., not detectable. Percentages of divided cells are shown. (E) The ratio of M133 Treg/bulk Treg is shown. The data are representative of three independent experiments (A, C, D) or pooled from three experiments (E). (F) 26105 M133 or Bulk Tregs were transferred to Thy1.1 mismatched mice and expression levels of indicated markers on transferred cells in the DCLN at day 4 p.i. are shown. To analyze bulk Tregs, cells from 5 recipient mice were pooled. Data are representative of analyses of three individual recipients (M133 Tregs) and 2 pooled samples (bulk Tregs). doi:10.1371/journal.ppat.1004279.g001
  • Figure 2. Initial proliferation of M133 Tconv occurs in the DCLN. (A) Experimental design. 16105 CFSE labeled M133 Tconv (Treg-depleted CD4 T cells) were transferred to Thy1 congenic mice one day prior to rJ2.2 infection. (B) Representative plots showing proliferation of transferred cells and CXCR3 expression. (C) CFSE levels on transferred cells at several times p.i. MFI, mean fluorescence intensity. (D, E) Frequency (D) and numbers (E) of M133 Tconv at the indicated times after infection. The data are representative of four independent experiments with 3 mice per time point in each. doi:10.1371/journal.ppat.1004279.g002
  • Figure 3. Initial proliferation of M133 Tregs in the DCLN is delayed compared to M133 Tconv. (A) Experimental design. M133 Tregs and M133 Tconv (Treg-depleted CD4 T cells) were mixed at a 2:1 ratio and labeled with Violet. 2.256105 cells were transferred to Thy1 congenic mice one day prior to infection with rJ2.2. (B) Representative plots showing proliferation of M133 Tconv and Treg. (C) Ratio of M133 Tconv/Treg in several organs at various times p.i. (D) Dot plot showing entry of M133 Treg and Tconv into the infected brain at early times p.i. Percentages of M133 Treg and Tconv after gating on transferred cells are shown. (E) Representative plot showing proliferation of M133 Tconv and Treg in mice infected with rJ2.2.MY135Q, which lacks epitope M133 expression, at day 5 p.i. (F) Representative plot showing CXCR3 expression by M133 Treg as they proliferate. The data are representative of four (B, C, D, F, three mice per time point) or one (E, four individual mice) independent experiments. doi:10.1371/journal.ppat.1004279.g003
  • Figure 4. M133 Tconv and Treg proliferation occurs in DCLN and CLN after FTY720 treatment. (A) Experimental design. M133 Tregs and M133 Tconv were mixed at a 1:1 ratio and labeled with Violet. 1.56105 cells were transferred to Thy1 congenic mice one day prior to infection with rJ2.2. Mice were treated with FTY720 or saline 0.5 hour prior to infection and on days 1, 2, 3 p.i. (B) Representative plots showing Violet dilution at day 4 p.i. Numbers are percentage of divided Tregs (upper) or Tconv (lower). (C) Summary of data from three independent experiments with three mice in each. doi:10.1371/journal.ppat.1004279.g004
  • Figure 5. M133 Tregs modulate M133 Tconv accumulation in the DCLN, spleen and brain. (A) Experimental design. M133 Tconv alone or a mixture of M133 Tconv and bulk Tregs or M133 Tconv and M133 Tregs (1:2 ratio) were labeled with Violet. After labeling, 0.756105 M133 Tconv or 2.256105 mixed cells were transferred into Thy1 congenic mice one day prior to rJ2.2 infection. (B) Numbers of M133 Tconv in DCLN, spleen and brain of recipient mice at the indicated times p.i. The data in B are representative of 3 independent experiments with 3–4 mice/time point. Asterisks indicate statistical significance when mice receiving M133 Tconv and M133 Tregs were compared to those receiving only M133 Tconv or M133 Tconv and bulk Tregs. *P,0.05, **P,0.01, ***P,0.001. doi:10.1371/journal.ppat.1004279.g005
  • Figure 6. M133 Tregs inhibit M133 Tconv proliferation in, and egress from, the DCLN. M133 Tconv or M133 Tconv and M133 Tregs (1:2 ratio) were labeled with Violet and transferred into Thy1 congenic mice prior to rJ2.2 infection as described in Figure 5A. Organs were harvested at the indicated time points and lymphocyte populations examined directly ex vivo. (A) Representative plots showing gating of transferred M133 Tconv (GFP2) in the absence (black) or presence of (red) co-transferred M133 Tregs, and of M133 Tregs (GFP+, blue). These gates and colors were applied in B–E. (B) Representative dot plots show CD69 and CD25 expression on M133 Tconv and M133 Tregs in DCLN at day 3 p.i. Boxed cells are positive for CD69 or CD25 expression. Summary data show expression levels of CD69 and CD25 on undivided and divided M133 Tconv. (C) Overlayed histograms showing proliferation of M133 Tconv in the absence or presence of co-transferred M133 Tregs in DCLN and spleen at days 3, 4 and 5 p.i. Expansion index (EI) of M133 Tconv was calculated using Flowjo software. (D) Apoptosis of M133 Tconv in the DCLN at day 4 p.i. was analyzed by Annexin V/7-AAD staining. (E) CXCR3 and Tbet levels on M133 Tconv and M133 Tregs in DCLN at day 4 p.i. The data in B-E are representative of 2–6 independent experiments with 3–5 mice/time point. *P,0.05, ***P,0.001. doi:10.1371/journal.ppat.1004279.g006
  • Figure 7. M133 Tconv and Tregs exhibit differential kinetics of T-bet and cytokine expression in DCLN. Violet labeled M133 Tconv (0.756105) or M133 Tregs (1.56105) were transferred to Thy1 congenic mice one day prior to rJ2.2 infection. DCLN cells were pooled from six recipient mice at day 3.5 after infection. Cells were examined for T-bet expression directly ex vivo or for IFN-c and IL-10 expression after M133 peptide stimulation. G0: generation 0, G1: generation 1, etc. Dot plots show T-bet and cytokine expression by M133 Tconv and Tregs as they proliferate. Data are representative of two independent experiments. doi:10.1371/journal.ppat.1004279.g007
  • Figure 8. Transferred M133 Tregs enhance survival and diminish the M133 Tconv immune response in the brain. 105 M133 Tregs, bulk Tregs or B6-derived Foxp32CD4 T cells (control group) were transferred to Thy1 congenic mice one day prior to rJ2.2 infection. (A) M133 Treg numbers in spleen, DCLN and brain of recipient mice from days 0 to 41 p.i. (B–D) Survival (B), weight loss (C) and viral titers in the brains (D) of recipient mice were monitored. 18–22 mice in 4 independent experiments were analyzed for survival and weight loss. In (C), *P,0.05, **P,0.01 weights of M133 Treg recipients compared to mice that received bulk Tregs or control cells; (E–G) Lymphocytes were prepared from brains of recipient mice at day 7 p.i. and stimulated with the indicated peptides. (E) Frequencies of S510 and S598-specific cells within the CD8 T cell population and M133- and S358-specific cells within the CD4 T cell population are shown. 6–10 mice in 3–5 independent experiments were analyzed. (F) Brain-derived lymphocytes were harvested from mice that received control cells or M133 Tregs. Representative dot plots show IFN-c and IL-10 expression by endogenous CD4 T cells after M133 peptide stimulation. Summary data show expression levels of IFN-c by M133-specific CD4 T cells in the absence (black) or presence (red) of M133 Treg. (G) Representative dot plots (from the same sample as in F (right hand dot plot)) show IFN-c and IL-10 expression by exogenous M133 Tregs. Note that lower levels of IFN-c were expressed by M133 Tregs when compared to Tconv. Summary data show expression levels of IL-10 by IFN-c- (black) and IFN-c+ M133 Tregs (red). Data in (F) and (G) are representative of three independent experiments with at least 3 mice/group. (H) Expression levels of MHC II on brain microglia at day 7 p.i. Data are representative of three independent experiments with 3–5 mice/group. *P,0.05, **P,0.01, ***P,0.001. doi:10.1371/journal.ppat.1004279.g008

References Powered by Scopus

2642Citations
3116Readers
Get full text

This article is free to access.

Get full text

Cited by Powered by Scopus

This article is free to access.

Get full text

This article is free to access.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Zhao, J., Zhao, J., & Perlman, S. (2014). Virus-Specific Regulatory T Cells Ameliorate Encephalitis by Repressing Effector T Cell Functions from Priming to Effector Stages. PLoS Pathogens, 10(8). https://doi.org/10.1371/journal.ppat.1004279

Readers over time

‘14‘15‘16‘17‘19‘20‘21‘2308162432

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 18

64%

Researcher 6

21%

Professor / Associate Prof. 4

14%

Readers' Discipline

Tooltip

Medicine and Dentistry 9

33%

Agricultural and Biological Sciences 8

30%

Immunology and Microbiology 7

26%

Nursing and Health Professions 3

11%

Save time finding and organizing research with Mendeley

Sign up for free
0